IDEXX Laboratories (Germany) Performance
| IX1 Stock | EUR 374.60 0.30 0.08% |
The company retains a Market Volatility (i.e., Beta) of -0.3, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning IDEXX Laboratories are expected to decrease at a much lower rate. During the bear market, IDEXX Laboratories is likely to outperform the market. At this point, IDEXX Laboratories has a negative expected return of -0.12%. Please make sure to check out IDEXX Laboratories' coefficient of variation, information ratio, total risk alpha, as well as the relationship between the standard deviation and jensen alpha , to decide if IDEXX Laboratories performance from the past will be repeated in the future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days IDEXX Laboratories has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 144.5 M |
IDEXX |
IDEXX Laboratories Relative Risk vs. Return Landscape
If you would invest 40,760 in IDEXX Laboratories on December 17, 2024 and sell it today you would lose (3,300) from holding IDEXX Laboratories or give up 8.1% of portfolio value over 90 days. IDEXX Laboratories is currently producing negative expected returns and takes up 2.0496% volatility of returns over 90 trading days. Put another way, 18% of traded stocks are less volatile than IDEXX, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
IDEXX Laboratories Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IDEXX Laboratories' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as IDEXX Laboratories, and traders can use it to determine the average amount a IDEXX Laboratories' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0585
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IX1 |
Estimated Market Risk
| 2.05 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average IDEXX Laboratories is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IDEXX Laboratories by adding IDEXX Laboratories to a well-diversified portfolio.
IDEXX Laboratories Fundamentals Growth
IDEXX Stock prices reflect investors' perceptions of the future prospects and financial health of IDEXX Laboratories, and IDEXX Laboratories fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IDEXX Stock performance.
| Return On Equity | 1.05 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 35.12 B | |||
| Shares Outstanding | 82.9 M | |||
| Price To Earning | 57.45 X | |||
| Price To Book | 75.09 X | |||
| Price To Sales | 9.95 X | |||
| Revenue | 3.37 B | |||
| EBITDA | 1.01 B | |||
| Cash And Equivalents | 116.62 M | |||
| Cash Per Share | 1.36 X | |||
| Total Debt | 694.39 M | |||
| Book Value Per Share | 7.34 X | |||
| Cash Flow From Operations | 542.98 M | |||
| Earnings Per Share | 7.59 X | |||
| Total Asset | 2.75 B | |||
About IDEXX Laboratories Performance
By analyzing IDEXX Laboratories' fundamental ratios, stakeholders can gain valuable insights into IDEXX Laboratories' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if IDEXX Laboratories has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IDEXX Laboratories has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine. IDEXX Laboratories operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange. It employs 8000 people.Things to note about IDEXX Laboratories performance evaluation
Checking the ongoing alerts about IDEXX Laboratories for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IDEXX Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IDEXX Laboratories generated a negative expected return over the last 90 days | |
| Over 93.0% of the company shares are owned by institutional investors |
- Analyzing IDEXX Laboratories' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IDEXX Laboratories' stock is overvalued or undervalued compared to its peers.
- Examining IDEXX Laboratories' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IDEXX Laboratories' management team can have a significant impact on its success or failure. Reviewing the track record and experience of IDEXX Laboratories' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IDEXX Laboratories' stock. These opinions can provide insight into IDEXX Laboratories' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |